Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Melody Trexler-Schmidt
Advertisement
Melody Trexler-Schmidt is a scientist in late-stage purification at Genentech, Inc.
Articles by Melody Trexler-Schmidt
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Applying Analytical Quality by Design Principles to Biopharma Method Development and Optimization
2
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
3
Why Radiopharmaceuticals Are Ideal for Treating Cancer
4
Check Your Knowledge: Patient-Centric Care Through Oral Liquid Delivery
5
